Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …

Monitoring treatment responses in chronic myeloid leukemia (CML) is based on complete
blood counts (CBCs) to determine hematologic response, karyotyping of bone marrow …

Currently, physicians treating chronic myeloid leukaemia (CML) patients can rely on a wide
spectrum of therapeutic options: the best use of such options is essential to achieve …

With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid
leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the …

In chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitors (TKIs) may select for
drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is …

Abstract BCR-ABL1 kinase domain (KD) mutation status is considered to be an important
element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do …

Molecular monitoring plays an essential role in the clinical management of chronic myeloid
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …

Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation
in patients with deep molecular response (DMR) is a paramount goal in the current chronic …

Purpose The advent of tyrosine kinase inhibitor (TKI) therapies has revolutionized the
treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) …

Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has
advanced to a stage where many patients achieve very low or undetectable levels of …